JP6496243B2 - Ｉｉｉ型分泌系を使用したペプチド発現および精製のための組成物および方法 - Google Patents

Ｉｉｉ型分泌系を使用したペプチド発現および精製のための組成物および方法 Download PDF

Info

Publication number
JP6496243B2
JP6496243B2 JP2015515191A JP2015515191A JP6496243B2 JP 6496243 B2 JP6496243 B2 JP 6496243B2 JP 2015515191 A JP2015515191 A JP 2015515191A JP 2015515191 A JP2015515191 A JP 2015515191A JP 6496243 B2 JP6496243 B2 JP 6496243B2
Authority
JP
Japan
Prior art keywords
flgm
nucleic acid
acid sequence
secretion
cleavage site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015515191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523066A5 (cg-RX-API-DMAC10.html
JP2015523066A (ja
Inventor
ケリー ティー ヒューズ
ケリー ティー ヒューズ
バルドメロ エム オリヴェラ
バルドメロ エム オリヴェラ
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション, ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2015523066A publication Critical patent/JP2015523066A/ja
Publication of JP2015523066A5 publication Critical patent/JP2015523066A5/ja
Application granted granted Critical
Publication of JP6496243B2 publication Critical patent/JP6496243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015515191A 2012-05-30 2013-05-30 Ｉｉｉ型分泌系を使用したペプチド発現および精製のための組成物および方法 Active JP6496243B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261689284P 2012-05-30 2012-05-30
US61/689,284 2012-05-30
PCT/US2013/043384 WO2013181404A2 (en) 2012-05-30 2013-05-30 COMPOSITIONS AND METHODS FOR PEPTIDE EXPRESSION AND PURIFICATION USING A TYPE lll SECRETION SYSTEM

Publications (3)

Publication Number Publication Date
JP2015523066A JP2015523066A (ja) 2015-08-13
JP2015523066A5 JP2015523066A5 (cg-RX-API-DMAC10.html) 2016-07-21
JP6496243B2 true JP6496243B2 (ja) 2019-04-03

Family

ID=49674058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515191A Active JP6496243B2 (ja) 2012-05-30 2013-05-30 Ｉｉｉ型分泌系を使用したペプチド発現および精製のための組成物および方法

Country Status (7)

Country Link
US (2) US9630997B2 (cg-RX-API-DMAC10.html)
EP (1) EP2855676B1 (cg-RX-API-DMAC10.html)
JP (1) JP6496243B2 (cg-RX-API-DMAC10.html)
DK (1) DK2855676T3 (cg-RX-API-DMAC10.html)
ES (1) ES2861275T3 (cg-RX-API-DMAC10.html)
PL (1) PL2855676T3 (cg-RX-API-DMAC10.html)
WO (1) WO2013181404A2 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6496243B2 (ja) * 2012-05-30 2019-04-03 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Ｉｉｉ型分泌系を使用したペプチド発現および精製のための組成物および方法
JP6938482B2 (ja) * 2015-10-02 2021-09-22 ユニバーシティー オブ ユタ リサーチ ファンデーション 調節可能なリボソーム翻訳速度のための組成物および使用法
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
CN108837152B (zh) * 2018-05-23 2021-06-22 浙江大学 鞭毛主调控基因flhDC或其表达产物作为靶点在抗菌药物开发中的应用
WO2020180800A1 (en) * 2019-03-04 2020-09-10 The Board Of Trustees Of The Leland Stanford Junior University Engineered cd47 extracellular domain for bioconjugation
JP2023546022A (ja) 2020-10-08 2023-11-01 ジーバイオティクス カンパニー 腸内での繊維合成酵素の発現のための操作されたプロバイオティクス
KR102933213B1 (ko) * 2022-07-21 2026-03-03 충남대학교산학협력단 코난토킨-g의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 약독화 살모넬라 균주
KR20240013955A (ko) * 2022-07-21 2024-01-31 충남대학교산학협력단 멜리틴 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 약독화 살모넬라 균주
KR20240015034A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 Stichodactyla 독소 분비를 위한 재조합 발현 벡터및 이로 형질전환된 약독화 살모넬라 균주
KR20240015029A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 카탈레이스 분비를 위한 재조합 발현 벡터 및 이로형질전환된 대장균 균주

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659102B2 (en) * 2001-02-21 2010-02-09 Verenium Corporation Amylases, nucleic acids encoding them and methods for making and using them
US20040033608A1 (en) * 2001-10-10 2004-02-19 Purdue Research Foundation Plasmids, strains, and methods of use
WO2003033536A2 (en) * 2001-10-19 2003-04-24 Paradigm Therapeutics Limited G-protein coupled receptor
US20120027786A1 (en) * 2010-02-23 2012-02-02 Massachusetts Institute Of Technology Genetically programmable pathogen sense and destroy
JP6496243B2 (ja) * 2012-05-30 2019-04-03 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Ｉｉｉ型分泌系を使用したペプチド発現および精製のための組成物および方法

Also Published As

Publication number Publication date
EP2855676A4 (en) 2016-04-06
US20150225466A1 (en) 2015-08-13
ES2861275T3 (es) 2021-10-06
JP2015523066A (ja) 2015-08-13
DK2855676T3 (da) 2021-04-12
US20180009851A1 (en) 2018-01-11
US9630997B2 (en) 2017-04-25
HK1209158A1 (en) 2016-03-24
WO2013181404A3 (en) 2015-06-04
WO2013181404A2 (en) 2013-12-05
PL2855676T3 (pl) 2021-07-05
EP2855676B1 (en) 2021-01-13
EP2855676A2 (en) 2015-04-08
US10800818B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
US10800818B2 (en) Compositions and methods for peptide expression and purification using a type III secretion system
Ma et al. An IcmF family protein, ImpLM, is an integral inner membrane protein interacting with ImpKL, and its walker a motif is required for type VI secretion system-mediated Hcp secretion in Agrobacterium tumefaciens
Bunikis et al. An RND-type efflux system in Borrelia burgdorferi is involved in virulence and resistance to antimicrobial compounds
Ishii et al. Nascent chain-monitored remodeling of the Sec machinery for salinity adaptation of marine bacteria
Fischer et al. The FtsH protease is involved in development, stress response and heat shock control in Caulobacter crescentus
CN107001431B (zh) 基于细菌的蛋白质递送
US20070020625A1 (en) Sequence of the photorhabdus luminescens strain tt01 genome and uses
JP2016501550A (ja) Ｃｒｍ１９７に関する方法及び組成物
Zhang et al. Functional characterisation of altered outer membrane proteins for tetracycline resistance in Escherichia coli
Guo et al. Analysis of factors that affect FlgM-dependent type III secretion for protein purification with Salmonella enterica serovar Typhimurium
WO2018195136A1 (en) Compositions and methods for regulated gene expression
Gao et al. The signal peptide of Cry1Ia can improve the expression of eGFP or mCherry in Escherichia coli and Bacillus thuringiensis and enhance the host’s fluorescent intensity
EP3286208A1 (en) Modified microorganisms expressing saga as anti-infective agents, probiotics and food components
EP4361172A2 (en) Expression vector for recombinant u-conotoxin tiiia or tiiialamut expression in e.coli
Peng et al. XrvB regulates the type III secretion system by directly repressing hrpG transcription in Xanthomonas oryzae pv. oryzicola
KR102809778B1 (ko) 조절가능한 리보솜 번역 속도를 위한 조성물 및 사용 방법
HK1209158B (en) COMPOSITIONS AND METHODS FOR PEPTIDE EXPRESSION AND PURIFICATION USING A TYPE lll SECRETION SYSTEM
KR20090018315A (ko) 대장균 유래 ｐｔｓＬ 프로모터를 함유하는 재조합벡터 및이를 이용한 외래 단백질의 제조방법
Lyu et al. Disruption of Protein BA_3317 Affects Asymmetric Division as an Exporter of Sporulation Signal Molecules in Bacillus anthracis
Wu et al. The archaic chaperone–usher pathways may depend on donor strand exchange for intersubunit interactions
AU2024340939A1 (en) Expression vector for recombinant µ-conotoxin TIIIA or TIIIAlaMut expression in E.coli
Flynn Holin-dependent secretion of a large clostridial cytotoxin by C. perfringens
Malik Understanding the molecular basis for adhesion by Haemophilus Surface Fibril
Zhang et al. Contribution of two-component response regulator OmpR to virulence, motility, exopolysaccharide production, and osmotic stress in Pseudomonas syringae pv. actinidiae
Lundberg Biochemical and functional characterization of MISTIC

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180514

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190308

R150 Certificate of patent or registration of utility model

Ref document number: 6496243

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250